Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Wearable Core Body Temperature Monitoring for Early Detection of Cytokine Release Syndrome in Outpatients Receiving CAR T-Cell Therapy

2 de noviembre de 2026 actualizado por: Wake Forest University Health Sciences

A Randomized Controlled Trial of a Wearable Core Body Temperature Sensor Versus Standard Temperature Monitoring for Early Detection of Cytokine Release Syndrome in Patients Undergoing CAR T-Cell Therapy in an Outpatient Setting

The purpose of this research study is to see if a wearable temperature monitoring patch can detect cytokine release syndrome earlier than traditional oral temperature monitoring.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Descripción detallada

This randomized pilot study is designed to evaluate the efficacy of a continuous temperature-monitoring wearable patch in patients receiving CAR-T therapy in the outpatient setting, comparing its performance to standard institutional monitoring protocols.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

105

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

    • North Carolina
      • Charlotte, North Carolina, Estados Unidos, 28204
        • Atrium Health Levine Cancer
        • Investigador principal:
          • Cindy Varga, MD
        • Contacto:
      • Winston-Salem, North Carolina, Estados Unidos, 27103
        • Atrium Health Wake Forest Baptist Comprehensive Cancer Center
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

Patients:

  1. Ability to understand and willingness to sign an IRB-approved informed consent
  2. Age ≥ 18 years at the time of consent
  3. Scheduled to undergo CAR-T therapy in the outpatient setting at AHWFBCCC
  4. Ability to read and understand the English and/or Spanish language
  5. As determined by the enrolling investigator, ability of the participant to understand and comply with study procedures for the entire length of the study
  6. Access to a mobile device for the duration of the trial

Provider/Staff:

Provider/staff participants must meet all of the following inclusion criteria to participate in the study:

  1. Verbally agree to participate
  2. Hospital at Home outpatient provider/advanced practice provider/nurse of at least one patient participant enrolled on Arm A who completed 14 days of temperature monitoring

Exclusion Criteria:

Patients:

  1. Planned prophylactic tocilizumab for mitigation of CRS as documented in the clinical trials pathway submission
  2. History of silicone allergy
  3. History of Medical Adhesive-Related Skin Injury (MARSI)
  4. Known skin condition that might preclude safe application of the patch, in the opinion of the enrolling investigator

Provider/Staff:

None

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Cuidados de apoyo
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Otro: Arm A: TempShield Continuous Temperature Monitoring plus SOC Temperature Monitoring

Standard of care oral temperature monitoring plus TempShield continuous temperature monitoring patch

Patient participants will receive instruction from a research designee regarding use of the TempShield patch and smartphone application for continuous at-home temperature monitoring. Patient participants will complete onboarding of the application on their smartphone with assistance from the research designee, if necessary. Patient participants should place the patch immediately after completion of CAR-T infusion in the outpatient setting, with assistance from the research designee.

Otro: Arm B: SOC Temperature Monitoring

Standard of care oral temperature monitoring

Standard of care oral temperature monitoring

Sin intervención: Arm C: Provider/Staff

Providers/staff are Hospital at Home personnel who support patients undergoing outpatient CAR-T therapy and who have monitored at least one participant enrolled on Arm A of the study.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Time to first recorded temperature elevation indicative of Cytokine Release Syndrome (CRS)
Periodo de tiempo: From the initiation of CAR-T infusion up to Day 14 post-infusion.

Time (in hours) from the initiation of CAR-T infusion to the first occurrence of a recorded body temperature elevation of ≥ 100.4°F (38.0°C) during the 14-day post-CAR-T observation period. Participants who do not experience this defined temperature elevation within the 14 days will be censored at the time of their last recorded temperature reading during this window. Reported by arm.

From the initiation of CAR-T infusion up to Day 14 post-infusion.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Incidence of temperature elevation indicative of Cytokine Release Syndrome (CRS)
Periodo de tiempo: From the initiation of CAR-T infusion up to Day 14 post-infusion.

Number of participants who experience at least one recorded body temperature elevation of ≥ 100.4°F (38.0°C) during the 14-day post-CAR-T observation period. Reported by arm.

From the initiation of CAR-T infusion up to Day 14 post-infusion.
Incidence of high-grade (grade 2 or higher) Cytokine Release Syndrome (CRS)
Periodo de tiempo: From the initiation of CAR-T infusion up to Day 14 post-infusion.

Number of participants who experience grade 2 or higher CRS during the 14-day post-CAR-T observation period. Reported by arm.

From the initiation of CAR-T infusion up to Day 14 post-infusion.
Time to resolution of Cytokine Release Syndrome (CRS) from temper elevation indicative of CRS (temperature ≥ 100.4 °F)
Periodo de tiempo: From the temperature elevation (≥ 100.4 °F) to resolution during the 14 days after CAR-T infusion.

Time (in hours) from the from onset of fever indicative of CRS (temperature ≥ 100.4 °F) during the 14-day post-CAR-T observation period to resolution (i.e., when the participant no longer meets the CRS diagnostic criteria). If a participant experiences multiple episodes of CRS during the 14-day post-CAR-T observation period, the duration can be calculated per episode and cumulatively. This will be calculated for participants experiencing CRS (temperature ≥ 100.4 °F) during the 14-day post-CAR-T observation period. Reported by arm.

From the temperature elevation (≥ 100.4 °F) to resolution during the 14 days after CAR-T infusion.
Time to intervention after fever detection (temperature ≥ 100.4 °F)
Periodo de tiempo: From the temperature elevation (≥ 100.4 °F) to intervention during the 14 days after CAR-T infusion.

Time (in hours) from documented temperature elevation of ≥ 100.4° F to clinician intervention (e.g., supportive care, medication followed by observation, etc.). This will be calculated for participants experiencing CRS during the 14-day post-CAR-T observation period. Reported by arm.

From the temperature elevation (≥ 100.4 °F) to intervention during the 14 days after CAR-T infusion.
Incidence of admission to the Intensive Care Unit (ICU) due to temperature elevation indicative of CRS
Periodo de tiempo: From the initiation of CAR-T infusion up to Day 14 post-infusion.

Number of participants admitted to the ICU due to temperature elevation indicative of CRS during the 14-day post-CAR-T observation period. Reported by arm.

From the initiation of CAR-T infusion up to Day 14 post-infusion.
Time to discharge after admission to the Intensive Care Unit (ICU)
Periodo de tiempo: From the initiation of CAR-T infusion up to Day 14 post-infusion.

Time (in hours) from ICU admission to ICU discharge. If a participant has multiple ICU admissions during the 14-day post-CAR-T observation period, the duration will be calculated cumulatively. Reported by arm.

From the initiation of CAR-T infusion up to Day 14 post-infusion.
Length of hospital stay
Periodo de tiempo: From the initiation of CAR-T infusion up to Day 14 post-infusion.

Number of inpatient nights from hospital admission to hospital discharge due to temperature elevation indicative of CRS during the 14-day post-CAR-T observation period. If a participant has multiple hospital admissions due to CRS during the 14-day post-CAR-T observation period, the duration reported will be cumulative across all stays. This endpoint will be calculated for participants admitted to this hospital during the 14-day post-CAR-T observation period due to temperature elevation indicative of CRS. Reported by arm.

From the initiation of CAR-T infusion up to Day 14 post-infusion.
Incidence of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Periodo de tiempo: From the initiation of CAR-T infusion up to Day 14 post-infusion.

Number of participants experiencing ICANS during the 14-day post-CAR-T observation period. Reported by arm.

From the initiation of CAR-T infusion up to Day 14 post-infusion.
Largest change in body temperature from baseline recorded during the 14-day post-CAR-T observation period
Periodo de tiempo: From the initiation of CAR-T infusion up to Day 14 post-infusion.

The maximum numerical difference in body temperature recorded from baseline during the 14-day post-CAR-T observation period. Reported by arm.

From the initiation of CAR-T infusion up to Day 14 post-infusion.
The proportion of hours during the 14-day post CAR-T observation period when patch was worn
Periodo de tiempo: From the initiation of CAR-T infusion up to Day 14 post-infusion.

The proportion of hours during the 14-day post-CAR-T observation period in which at least one valid human body temperature reading (86 °F to 108 °F) was recorded by the wearable patch, defined as Total adherence = (Number of hours with at least one valid temperature reading)/(24*14 hours). This will be calculated for participants randomized to wear the remote temperature monitoring device.

From the initiation of CAR-T infusion up to Day 14 post-infusion.
The proportion of paired temperature readings from the temperature patch and an oral thermometer within one degree Fahrenheit in a five-minute window during the 14-day post-CAR-T observation period
Periodo de tiempo: From the initiation of CAR-T infusion up to Day 14 post-infusion.

The number 5-minute intervals in the 14-day post-CAR-T observation period (from the first patch reading indicating a temperature from 86 °F to 108 °F), when concordance between the temperature patch and an oral thermometer within one degree Fahrenheit was observed.

From the initiation of CAR-T infusion up to Day 14 post-infusion.
Patient satisfaction with CAR-T temperature monitoring methods
Periodo de tiempo: The Day 14 post-infusion (+28 days) study calendar visit.

Patient satisfaction as assessed by the study survey, evaluating satisfaction on a Likert scale where higher scores indicate a higher level of patient satisfaction with the assigned monitoring method (standard of care vs. wearable patch).

The Day 14 post-infusion (+28 days) study calendar visit.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Cindy Varga, MD, Wake Forest University Health Sciences

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de diciembre de 2026

Finalización primaria (Estimado)

1 de agosto de 2028

Finalización del estudio (Estimado)

2 de enero de 2029

Fechas de registro del estudio

Enviado por primera vez

26 de octubre de 2026

Primero enviado que cumplió con los criterios de control de calidad

26 de octubre de 2026

Publicado por primera vez (Actual)

2 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

5 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir